公开(公告)号：US12097213B2

公开(公告)日：2024-09-24

申请号：US17200539

申请日：2021-03-12

Applicant: The Board of Regents of the University of Texas System

Inventor： Jerry Shay ,  Yang-Xin Fu ,  Ilgen Mender ,  Anli Zhang

IPC: A61K31/7076 ,  A61N5/00 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K31/7076 ,  A61N5/00 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827

Abstract: Disclosed herein are methods of treatments with a telomerase-mediated telomere-targeting drug, 6-thio-2′-deoxyguanosine (6-thio-dG), checkpoint inhibitors and/or radiation therapy for treating cancers. Leads to tumor regression in innate and adaptive immune-dependent manners in syngeneic and humanized mouse cancer models.

公开(公告)号：US12070472B2

公开(公告)日：2024-08-27

申请号：US16450430

申请日：2019-06-24

Applicant: The Board of Regents of the University of Texas System

Inventor： Jerry Shay ,  Ilgen Mender ,  Kimberly Batten ,  Sergei Gryaznov

IPC: A61K31/7076 ,  A61K9/00 ,  A61K31/7105 ,  A61K45/06

CPC classification number: A61K31/7076 ,  A61K9/0019 ,  A61K31/7105 ,  A61K45/06

Abstract: The described invention is directed toward pharmaceutical compositions and methods of using 6-mercaptopurine ribosides and analogues thereof for the treatment of cancer and other hyperproliferative diseases. The described compounds can be converted into telomere substrates in vivo and can be recognized by telomerase for incorporation into telomeres of telomerase active cells, leading to induction of cell death of the telomerase active cells.

公开(公告)号：US20210290652A1

公开(公告)日：2021-09-23

申请号：US17200539

申请日：2021-03-12

Applicant: The Board of Regents of the University of Texas System

Inventor： Jerry Shay ,  Yang-Xin Fu ,  Ilgen Mender ,  Anli Zhang

IPC: A61K31/7076 ,  A61P35/00 ,  C07K16/28 ,  A61N5/00

Abstract: Disclosed herein are methods of treatments with a telomerase-mediated telomere-targeting drug, 6-thio-2′-deoxyguanosine (6-thio-dG), checkpoint inhibitors and/or radiation therapy for treating cancers. eads to tumor regression in innate and adaptive immune-dependent manners in syngeneic and humanized mouse cancer models.

公开(公告)号：US20180036331A1

公开(公告)日：2018-02-08

申请号：US15467862

申请日：2017-03-23

Applicant: The Board of Regents of the University of Texas System ,  Elizabeth Therapeutics LLC

Inventor： Jerry Shay ,  Ilgen Mender ,  Kimberly Batten ,  Cynthia Lander

IPC: A61K31/7076 ,  A61K9/00 ,  A61K31/7105 ,  A61K45/06

CPC classification number: A61K31/7076 ,  A61K9/0019 ,  A61K31/7105 ,  A61K45/06

Abstract: The described invention is directed toward pharmaceutical compositions and methods of using 6-mercaptopurine ribosides and analogues thereof for the treatment of cancer and other hyperproliferative diseases. The described compounds can be converted into telomere substrates in vivo and can be recognized by telomerase for incorporation into telomeres of telomerase active cells, leading to induction of cell death of the telomerase active cells.